[S-29] Symposium 29
Preparing for disease-modifying therapies in PD – From biomarkers, animal models to novel therapeutic approach

[S-29-1] Updates of Liquid biomarkers in PD

^○Chin-Hsien Lin, Chau-chung Wu, Ming-jang Chiu (National Taiwan University Hospital)

For the realization of disease-modifying therapies (DMT) in PD, appropriate animal models for the preclinical study and early and progression biomarkers in PD are essential. As a target of DMT much attention have been paid for mitochondria and alpha synuclein, especially. The aim of this symposium is, 1) to update recent findings in biomarkers and animal models in PD including its prodromal stage, and 2) to introduce novel therapeutic approach, focusing on mitochondria and alpha-synuclein which are the key players in idiopathic PD.

Dr. Chin-Hsien Lin graduated from College of Medicine, National Taiwan University. She received her PhD training from Institute of Molecular Biology, Academia Sinica, and investigated the molecular mechanisms of LRRK2 mutations in neurons by using a Drosophila model system. She received post-doctoral fellowship training in University of British Columbia, Canada. Dr. Lin is now a clinical associate professor in National Taiwan University Hospital. Her academic interests include genetic, biomarker and molecular biology studies of Parkinson’s disease. She is now an executive member of Taiwan Movement Disorders Society and a representative member of the leadership program of international Movement Disorder Society in 2015. She is now a member of educational committee of the Movement Disorder Society-Asian Oceanian Section.
Selected Bibliography (2017-2020)
1.Chin-Hsien Lin, Shieh-Yueh Yang, Herng-Er Horng, et al. Plasma α-synuclein predicts cognitive decline in Parkinson's disease. Journal of Neurology, Neurosurgery & Psychiatry 2017;88:818-824.
2.Chin-Hsien Lin, Pei-Lung Chen, Chun-Hwei Tai, et al. A clinical and genetic study of early-onset and familial parkinsonism in Taiwan: an integrated approach combining gene dosage analysis and next generation sequencing. Movement Disorders 2019;34:506-515.
3.Chin-Hsien Lin, Cheng-Hsuan Li, Kai-Chien Yang, et al. Blood NfL: A biomarker for disease severity and progression in Parkinson’s disease. Neurology Neurology. 2019;93(11):e1104-e1111.